These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10503800)

  • 1. Data monitoring committees and interim monitoring guidelines.
    Freidlin B; Korn EL; George SL
    Control Clin Trials; 1999 Oct; 20(5):395-407. PubMed ID: 10503800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 3. Data Monitoring Committees and early stopping guidelines: the Southwest Oncology Group experience.
    Crowley J; Green S; Liu PY; Wolf M
    Stat Med; 1994 Jul 15-30; 13(13-14):1391-9. PubMed ID: 7973218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
    Walter SD; Han H; Briel M; Guyatt GH
    Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some practical aspects of the interim monitoring of clinical trials.
    Simon R
    Stat Med; 1994 Jul 15-30; 13(13-14):1401-9. PubMed ID: 7973219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim analyses and stopping rules in cancer clinical trials.
    Whitehead J
    Br J Cancer; 1993 Dec; 68(6):1179-85. PubMed ID: 8260370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias.
    Tharmanathan P; Calvert M; Hampton J; Freemantle N
    BMC Med Res Methodol; 2008 Mar; 8():12. PubMed ID: 18366697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data monitoring committees, interim analysis and early termination in paediatric trials.
    Fernandes RM; van der Lee JH; Offringa M
    Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2).
    Briel M; Lane M; Montori VM; Bassler D; Glasziou P; Malaga G; Akl EA; Ferreira-Gonzalez I; Alonso-Coello P; Urrutia G; Kunz R; Culebro CR; da Silva SA; Flynn DN; Elamin MB; Strahm B; Murad MH; Djulbegovic B; Adhikari NK; Mills EJ; Gwadry-Sridhar F; Kirpalani H; Soares HP; Abu Elnour NO; You JJ; Karanicolas PJ; Bucher HC; Lampropulos JF; Nordmann AJ; Burns KE; Mulla SM; Raatz H; Sood A; Kaur J; Bankhead CR; Mullan RJ; Nerenberg KA; Vandvik PO; Coto-Yglesias F; Schünemann H; Tuche F; Chrispim PP; Cook DJ; Lutz K; Ribic CM; Vale N; Erwin PJ; Perera R; Zhou Q; Heels-Ansdell D; Ramsay T; Walter SD; Guyatt GH
    Trials; 2009 Jul; 10():49. PubMed ID: 19580665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stopping at nothing? Some dilemmas of data monitoring in clinical trials.
    Goodman SN
    Ann Intern Med; 2007 Jun; 146(12):882-7. PubMed ID: 17577008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
    Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
    J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting on data monitoring committees in neonatal randomised controlled trials is inconsistent.
    Perrem LM; Gosling S; Ravikumar I; Khashan AS; Miletin J; Ryan CA; Dempsey E
    Acta Paediatr; 2017 Jan; 106(1):30-33. PubMed ID: 27637413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Data monitoring committees and problems of lower-than-expected accrual or events rates.
    Korn EL; Simon R
    Control Clin Trials; 1996 Dec; 17(6):526-35. PubMed ID: 8974211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Policies for study monitoring and interim reporting of results.
    Green SJ; Fleming TR; O'Fallon JR
    J Clin Oncol; 1987 Sep; 5(9):1477-84. PubMed ID: 3625262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model for the interim analysis process: a case study.
    Delgado-Herrera L; Anbar D
    Control Clin Trials; 2003 Feb; 24(1):51-65. PubMed ID: 12559642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
    Ellenberg SS; George SL
    Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework.
    Blenkinsop A; Parmar MK; Choodari-Oskooei B
    Clin Trials; 2019 Apr; 16(2):132-141. PubMed ID: 30648428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interim analyses].
    Kramar A; Paoletti X
    Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.